AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

IMUGENE LIMITED Investor Presentation 2016

Jan 14, 2016

65124_rns_2016-01-14_e661548f-7411-451b-b2b7-c8a3bfb57faf.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

==> picture [167 x 75] intentionally omitted <==

Imugene to present at Noble Financial Capital Markets’ 12th Annual Investor Conference

Melbourne, Australia, 15 January 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, today announced that Leslie Chong, Chief Operating Officer of the company, will present at NobleCon12, the Noble Financial Capital Markets’ Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Fl., on Wednesday, January 20 2016 at 11 AM ET. Following the Conference on January 22, 2016, a high-definition video webcast of Imugene’s presentation and a copy of the presentation materials will be available on the Company's website, www.imugene.com, or as part of a complete catalog of presentations available at Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About Imugene and HER-Vaxx

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene’s lead product is HER-Vaxx , a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. For further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at http://www.twitter.com/TeamImugene.

About Noble Financial Capital Markets

Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer Tel: +61 458 040 433 (Australia), eslie.chong [at]imugene.com